Cellution Biologics for Wound Care: What the Evidence Actually Shows

Direct answer: "Cellution biologics" is not a product category a wound center can order. Searchers using the term are usually converging on one of two things: the Celution System — an automated point-of-care platform originally developed by Cytori Therapeutics for processing a patient's own adipose-derived regenerative cells (ADRCs) — or a general idea of "fat-derived stem cell therapy for wounds." In chronic wound care, ADRC approaches remain investigational: real trials exist (mostly small, with one completed registry-listed study of adipose-derived regenerative cell therapy for chronic wounds, NCT02092870), but there is no FDA-approved ADRC wound indication and no settled reimbursement pathway. Amniotic membrane and placental allografts, by contrast, are off-the-shelf HCT/Ps with multiple randomized-trial meta-analyses in diabetic foot ulcers (PMID 32119765; PMID 32715574), established storage and handling profiles, and product-specific HCPCS coding under the 2026 Medicare skin-substitute framework. For a formulary decision today, the two categories sit at very different points on the evidence-and-operations curve — the table below summarizes where.

| Dimension | Adipose-derived cell therapy (Celution-type ADRC/SVF) | Amniotic membrane / placental allografts | |---|---|---| | Product form | Autologous cells harvested and processed at point of care | Off-the-shelf human tissue allograft | | Best wound evidence | Small trials and phase II RCTs in DFU/chronic leg ulcers (NCT02092870; PMID 33826245; PMID 30583949) | Multiple systematic reviews and meta-analyses of RCTs in DFU (PMID 32119765; PMID 32715574; PMID 33588807) | | FDA status for wounds | Investigational — no approved wound indication | Section 361 HCT/Ps under 21 CFR Part 1271 | | Workflow per application | Liposuction harvest + cell processing + same-visit application | Topical application after wound bed preparation | | Storage / logistics | Requires harvesting procedure and processing time | Dehydrated forms store at room temperature | | Medicare billing | No product-specific skin-substitute code; investigational category | Product-specific HCPCS Q-codes within the 2026 flat-rate framework | | Availability | Limited to research or specific clinical programs | Distributor-supplied, stockable |

What the Term Refers To — and Why the Search Results Are Mixed

The word "Celution" belongs to the automated adipose-cell-processing lineage: the Celution System was developed to take a lipoaspirate sample and return a stromal vascular fraction (SVF) rich in regenerative cells within the same procedure. That is the technology family behind most "fat-derived stem cell" wound studies. Adding to the ambiguity, a similarly named company — CellGenuity (cellgenuity.com) — markets amniotic membrane products and appears in search results for this query despite being a tissue-product supplier rather than a cell-processing platform. A clinician or buyer searching "cellution biologics" is therefore usually trying to answer one question: is autologous fat-derived cell therapy a real option for chronic wounds, and how does it stack up against the allografts already on our shelf? This piece addresses that question directly.

The ADRC Evidence Base in Chronic Wounds

The signal is real but early. The most directly relevant registry entry is a completed study titled "Adipose Derived Regenerative Cellular Therapy of Chronic Wounds" (NCT02092870). The associated published series examined SVF cell injections in chronic diabetic foot ulcers and reported safety and evidence of efficacy at one year (PMID 33826245) — encouraging, but a small single-arm experience, not a pivotal trial. On the randomized side, a phase II trial treated recalcitrant chronic leg ulcers with centrifuged adipose tissue containing progenitor cells (PMID 30583949), and a registered trial of adipose-derived stem cells delivered on a biological matrix for venous leg ulcers (NCT05962931) is listed on the registry with an unknown status — a reminder that this literature is sparse and slow-moving.

Review authors converge on the same read: adipose-derived stem cells have strong mechanistic rationale for diabetic wound healing — angiogenic, immunomodulatory, and differentiable properties that map onto the biology of a stalled wound bed (PMID 37874529; PMID 30118878) — but clinical translation remains at the review-and-early-trial stage, with recent DFU-focused reviews calling for adequately powered controlled trials before standard-of-care claims can be made (PMID 40525423). In an evaluation framework, that places ADRC therapy in the "watch" tier: mechanistically credible, clinically unproven at scale.

How Amniotic Allografts Compare on Evidence Maturity

The allograft side of the comparison has something the cell-therapy side does not yet: synthesized randomized evidence. Systematic reviews and meta-analyses of RCTs have examined human amniotic membrane allograft in chronic diabetic foot ulcers and reported healing advantages over standard care alone (PMID 32119765; PMID 32715574), and structured reviews have mapped where amniotic allografts rationally fit in DFU treatment algorithms (PMID 33588807). Amniotic and placental products also sit inside the broader bioengineered-skin evidence base that procurement committees already evaluate (PMID 38592047), and real-world effectiveness studies of amniotic membrane allografts versus standard wound care across DFU, VLU, and pressure-injury populations are underway on the registry (NCT07223281). None of this makes any individual allograft automatically superior — product-level data still varies, and value analysis committees should demand it — but the category has the meta-analytic floor that autologous cell therapy for wounds has not yet built.

Our wound care biologics comparison for 2026 walks through the full category evaluation framework; the underlying biology of why amniotic tissue supports healing is covered in the amniotic membrane science guide.

Regulatory Pathway and Practical Operations

The two categories are regulated differently, and the difference shows up in the workflow. Amniotic membrane allografts used for homologous wound coverage are Section 361 HCT/Ps under 21 CFR Part 1271 — recovered, processed, and distributed under tissue-bank standards, with no premarket approval required for homologous use. ADRC therapy, because it involves more-than-minimal-manipulation of autologous tissue for non-homologous use, sits on the investigational side of FDA policy for SVF; using it outside a sanctioned study or approved indication carries genuine regulatory exposure, which is a material consideration for any clinic evaluating "stem cell wound therapy" offers.

Operationally, an allograft application is a topical procedure layered onto standard wound bed preparation. An ADRC treatment adds a harvest procedure, processing interval, and same-visit cell delivery — more steps, more time, more patient selection criteria (adequate adipose donor sites, anticoagulation considerations for harvest), and no shelf inventory.

Cost and Reimbursement Reality

Under the 2026 Medicare skin-substitute framework, amniotic allografts bill through product-specific HCPCS Q-codes within the flat-rate incident-to supply structure — a pathway procurement teams already know how to evaluate, with documentation requirements our Medicare coverage guide for advanced wound biologics covers in detail. Autologous ADRC preparations have no equivalent product-specific skin-substitute code; as an investigational category, the cell-processing component is generally not separately payable in outpatient wound care, and any program considering it should treat reimbursement as unestablished rather than assume coverage will follow.

Where This Leaves a Wound Program

Disclosure first: NextGen Biologics distributes amniotic membrane allografts — AmnioAMP and Rampart DL Matrix — so we write about the allograft side of this comparison from a declared position. That position does not change the evidence read above: adipose-derived cell therapy for chronic wounds is a credible research direction worth tracking (NCT02092870 and its successors are the studies to watch), and any clinic recruited into an unregulated "stem cell wound clinic" arrangement should be asking harder questions than the marketing typically invites. For formulary decisions being made this quarter, a category with RCT meta-analyses, room-temperature storage, established coding, and same-visit application remains the defensible default for adjunctive biologic coverage of hard-to-heal wounds.

Frequently asked questions Is the Celution System FDA-approved for wound healing? No. ADRC/SVF processing platforms and the wound applications studied with them remain investigational; there is no approved ADRC indication for wound healing in the United States. Is there a trial of adipose-derived cells in chronic wounds? Yes — a completed registry-listed study of adipose-derived regenerative cellular therapy of chronic wounds (NCT02092870) plus small published series in DFU (PMID 33826245) and a phase II RCT in recalcitrant leg ulcers (PMID 30583949). Evidence is early-stage, not practice-changing. How do I choose between categories for a value analysis review? Evaluate ADRC therapy as an investigational watch item and allografts as a stockable category with synthesized RCT evidence, 361 HCT/P regulation, and Q-code billing — then demand product-level outcomes data from any manufacturer, including ours.

Product specifications for the amniotic allograft side of this comparison are available on our product page. Request samples of AmnioAMP or Rampart for evaluation.